CVS Health (NYSE:CVS)‘s stock had its “hold” rating reissued by research analysts at Deutsche Bank in a research note issued to investors on Tuesday.

A number of other equities analysts also recently commented on the stock. Robert W. Baird reissued a “hold” rating and issued a $77.00 price objective on shares of CVS Health in a research note on Friday, October 27th. Needham & Company LLC raised shares of CVS Health from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $69.02 to $79.00 in a research note on Friday, November 10th. Mizuho set a $90.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. BidaskClub downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Finally, Loop Capital started coverage on shares of CVS Health in a research note on Thursday, August 24th. They issued a “hold” rating and a $83.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $86.35.

Shares of CVS Health (NYSE:CVS) opened at $71.69 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health has a 12 month low of $66.45 and a 12 month high of $84.72. The firm has a market cap of $76,095.96, a P/E ratio of 13.16, a PEG ratio of 1.29 and a beta of 0.89.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. The firm had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company’s revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.64 earnings per share. sell-side analysts expect that CVS Health will post 5.9 EPS for the current fiscal year.

In other news, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $81.17, for a total transaction of $1,667,799.99. Following the sale, the executive vice president now directly owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO David M. Denton sold 237,078 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the sale, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders sold 714,125 shares of company stock worth $58,119,381 over the last ninety days. Corporate insiders own 0.61% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in CVS Health by 1.4% in the second quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock valued at $6,159,825,000 after purchasing an additional 1,056,265 shares during the last quarter. FMR LLC boosted its holdings in CVS Health by 22.0% in the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock valued at $2,425,920,000 after purchasing an additional 5,446,930 shares during the last quarter. Bank of America Corp DE boosted its holdings in CVS Health by 1.8% in the first quarter. Bank of America Corp DE now owns 22,411,957 shares of the pharmacy operator’s stock valued at $1,759,338,000 after purchasing an additional 398,999 shares during the last quarter. Northern Trust Corp boosted its holdings in CVS Health by 5.5% in the second quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock valued at $1,256,631,000 after purchasing an additional 807,639 shares during the last quarter. Finally, Nordea Investment Management AB boosted its holdings in CVS Health by 8.4% in the second quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock valued at $1,138,905,000 after purchasing an additional 1,100,373 shares during the last quarter. 82.24% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “CVS Health (CVS) Rating Reiterated by Deutsche Bank” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/12/05/cvs-health-cvs-rating-reiterated-by-deutsche-bank.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.